Evaluation and Management of Proteinuria with Hematuria in Normotensive Patients
Diagnostic Workup
- The coexistence of proteinuria and hematuria markedly raises the probability of glomerular disease compared with either finding alone. 1
- A first‑morning spot urine protein‑to‑creatinine ratio (PCR) or albumin‑to‑creatinine ratio (ACR) should be obtained to quantify protein excretion accurately. [2][3]
- A PCR ≥ 0.3 mg/mg (≈30 mg/mmol) or an ACR ≥ 30 mg/mmol defines significant proteinuria that warrants further evaluation. [4][5]6
- When the spot ratio corresponds to ≥ 500 mg protein per 24 h (or ACR ≥ 30 mg/mmol), a nephrology referral is indicated. [7][8]
- Urine sediment analysis for dysmorphic red blood cells, red‑cell casts, and acanthocytes is essential; their presence is virtually pathognomonic for glomerular bleeding and indicates primary renal parenchymal disease. Phase‑contrast microscopy may be required for accurate assessment. [1][9]
- Serum creatinine should be measured and eGFR calculated using validated equations such as CKD‑EPI; elevated creatinine at presentation predicts a poorer prognosis. [3][9][10][11]
Nephrology Referral Criteria
- Immediate referral is recommended when any of the following are present:
Differential Diagnosis
- IgA nephropathy is the most frequent primary glomerulonephritis presenting with proteinuria and hematuria in the absence of hypertension. [10][11]12
- Other primary glomerular diseases (e.g., membranoproliferative glomerulonephritis) should also be considered when the above pattern is observed. 10
Initial Management While Awaiting Nephrology
- Initiate an ACE inhibitor or ARB when proteinuria is confirmed at ≥ 0.5–1 g/day, as these agents provide renoprotective effects even in normotensive patients. [10][11]
- Target blood pressure < 130/80 mmHg for proteinuria < 1 g/day and < 125/75 mmHg for proteinuria ≥ 1 g/day. [10][11]
Role of Renal Biopsy
- Renal biopsy is often required to obtain a definitive diagnosis, apply histologic scoring for prognosis, and guide immunosuppressive therapy decisions. [10][11]12